InflaRx (IFRX) Interest & Investment Income (2017 - 2026)
InflaRx (IFRX) posted Interest & Investment Income of $391928.2 for Q1 2026, down 13.96% sequentially from $455500.7 in Q4 2025, and down 24.54% YoY from $519382.7 in Q1 2025.
InflaRx (IFRX) Interest & Investment Income (2017 - 2026) Analysis & Trends
InflaRx has reported Interest & Investment Income for 10 years, with the latest figure at $391928.2 in Q1 2026.
- Quarterly Interest & Investment Income fell 24.54% year-over-year to $391928.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 34.91% YoY) and the FY2025 annual result came in at $2.1 million, down 39.74% from the prior year.
- Interest & Investment Income eased to $391928.2 in Q1 2026 per IFRX's latest filing, from $455500.7 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $489.5 billion in Q1 2023 and troughed at $31382.8 in Q1 2022.
- A 5-year average of $28.8 billion and a median of $591133.1 in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 1559715401.69% in 2023, then sank 100.0% in 2024.
- Over 5 years, Interest & Investment Income stood at $304603.0 in 2022, then surged by 278.64% to $1.2 million in 2023, then plunged by 37.52% to $720594.5 in 2024, then sank by 36.79% to $455500.7 in 2025, then decreased by 13.96% to $391928.2 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $391928.2, $455500.7, and $512202.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 895,786.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 391,928.18 |
| Dec 31, 2025 | 455,500.70 |
| Sep 30, 2025 | 512,202.78 |
| Jun 30, 2025 | 591,133.12 |
| Mar 31, 2025 | 519,382.67 |
| Dec 31, 2024 | 720,594.48 |
| Sep 30, 2024 | 843,790.60 |
| Jun 30, 2024 | 913,462.35 |
| Mar 31, 2024 | 986,879.27 |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 489.48 Bn |
| Dec 31, 2022 | 304,603.01 |
| Sep 30, 2022 | 201,410.86 |
| Jun 30, 2022 | 87,926.54 |
| Mar 31, 2022 | 31,382.81 |
| Dec 31, 2021 | 125.14 Bn |
| Sep 30, 2021 | 32,288.89 |
| Jun 30, 2021 | 42,898.56 |